Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Exchange Rate Effect (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Exchange Rate Effect for 17 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect rose 103.4% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $195.0 million through Dec 2025, up 242.34% year-over-year, with the annual reading at $195.0 million for FY2025, 242.34% up from the prior year.
  • Exchange Rate Effect for Q4 2025 was $5.0 million at Bristol Myers Squibb, up from -$4.0 million in the prior quarter.
  • The five-year high for Exchange Rate Effect was $128.0 million in Q2 2025, with the low at -$147.0 million in Q4 2024.
  • Average Exchange Rate Effect over 5 years is -$1.6 million, with a median of -$6.0 million recorded in 2023.
  • The sharpest move saw Exchange Rate Effect crashed 494.44% in 2022, then surged 681.82% in 2025.
  • Over 5 years, Exchange Rate Effect stood at -$54.0 million in 2021, then surged by 275.93% to $95.0 million in 2022, then fell by 17.89% to $78.0 million in 2023, then plummeted by 288.46% to -$147.0 million in 2024, then surged by 103.4% to $5.0 million in 2025.
  • According to Business Quant data, Exchange Rate Effect over the past three periods came in at $5.0 million, -$4.0 million, and $128.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.